Selvia Hanna | Clinical Pharmacy | Best Researcher Award

Dr. Selvia Hanna | Clinical Pharmacy | Best Researcher Award

Senior Clinical Pharmacist | Beni-Suef University Hospital | Egypt

๐Ÿ‘ฉโ€๐Ÿ”ฌ Short Bio:

Selvia Maher Farag Hanna is a dedicated Senior Clinical Pharmacist and Member of the Clinical Research Center at Beni-Suef University Hospital, specializing in Cardiology. With 12 years of experience, she excels in medication therapy management and improving patient outcomes through interdisciplinary collaboration.

Profile:

SCOPUS

๐Ÿ“š Education:

Selvia completed her Doctor of Philosophy in Pharmaceutical Sciences (Clinical Pharmacy) at Beni-Suef University in July 2024. She holds a Master’s degree in Pharmaceutical Sciences (Clinical Pharmacy) and a Bachelor’s degree in Pharmaceutical Sciences, both from Beni-Suef University.

๐Ÿ’ผ Experience:

Since July 2012, Selvia has served as a Clinical Pharmacist at Beni-Suef University Hospital, focusing on medication management in the Cardiology care unit. Previously, she worked at El-Masrya Pharmacy, gaining experience in medication counseling and drug utilization review.

๐Ÿ”ฌ Research Interest:

Selvia’s research interests revolve around Cardiology, specifically hypertension management, drug interactions, and patient-centric care strategies to enhance treatment efficacy and safety.

๐Ÿ† Award:

Recipient of the Distinguished Scientist Award for her contributions to Clinical Pharmacy and Cardiology research.

๐Ÿ“„ Publications:

  1. Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure
    Published in High Blood Pressure & Cardiovascular Prevention, November 2018.
    View Publication
    Cited 11 times.
  2. Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure
    Published in Current Hypertension Reviews, May 2023.
    View Publication
  3. Target Blood Pressure and Combination Therapy: Focus on Angiotensin Receptor Blockers Combination with Either Calcium Channel Blockers or Beta Blockers
    Published in Current Hypertension Reviews, September 2022.
  4. Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure
    Published in Hipertension y Riesgo Vascular, Januaryโ€“March 2024.

 

Gregory Madden | Infectious Diseases | Best Researcher Award

Dr. Gregory Madden | Infectious Diseases | Best Researcher Award

Assistant Professor |University of Virginia | United States

Short Bio ๐ŸŒ

Gregory Russell Madden is an Assistant Professor specializing in Infectious Diseases at the University of Virginia (UVA). His research focuses on hospital epidemiology and infectious disease management, with a particular emphasis on Clostridioides difficile infection. Dr. Madden is renowned for his work in diagnostic stewardship and immune profiling, aiming to improve patient outcomes through innovative research and clinical practice.

Profile

ORCID

Education ๐Ÿ“š

Dr. Madden completed his undergraduate studies at the University of Delaware, earning a B.A. in Biology & Biochemistry in June 2008. He subsequently obtained his Doctor of Medicine (M.D.) from the University of Virginia in June 2012. Following this, he pursued residency training in Internal Medicine at Yale University and completed a fellowship in Infectious Diseases at the University of Virginia, where he also obtained a Master’s degree in Data Science in August 2023.

Experience ๐Ÿ’ผ

As an Assistant Professor at UVA, Dr. Madden has been actively involved in clinical research and teaching. He has served as a hospitalist and instructor in Medicine at Beth Israel Deaconess Medical Center, Boston, and has held key roles in various committees and advisory boards focused on infection control and epidemiology. His expertise spans clinical diagnostics, antimicrobial resistance, and the application of data science in healthcare settings.

Research Interest ๐Ÿ”ฌ

Dr. Madden’s research interests revolve around understanding and mitigating healthcare-associated infections, particularly C. difficile infection. He has pioneered the use of diagnostic stewardship algorithms and immune profiling to predict infection outcomes, aiming to personalize treatment strategies and improve patient care. His work has been instrumental in advancing our understanding of pathogen-host interactions and developing targeted interventions.

Award ๐Ÿ†

In July 2021, Dr. Madden was awarded a prestigious K23 Mentored Career Development Award for his project titled ‘Immune profiling to stratify Clostridioides difficile infection outcomes’. This award recognizes his significant contributions to the field of infectious diseases and underscores his commitment to translational research that bridges basic science with clinical practice.

Publication ๐Ÿ“

Gregory Russell Madden has authored numerous influential publications, including:

  • Madden GR, German Mesner I, Cox HL, et al. Reduced Clostridium difficile Tests and Laboratory-Identified Events with a Computerized Clinical Decision Support Tool and Financial Incentive. Infect Control Hosp Epidemiol. 2018 Jun;39(6):737โ€“40. [PMC6088779]
  • Madden GR, Enfield KB, Sifri CD. Patient Outcomes Associated with Prevented versus Negative Clostridium difficile Tests Using Computerized Clinical Decision Support (CCDS). Open Forum Infect Dis. 2020 Mar 18;7(4):1-8. [PMC7166115]
  • Abhyankar MM, Ma JZ, Scully KW, et al. Immune Profiling To Predict Outcome of Clostridioides difficile Infection. mBio. 2020 May 26;11(3)

    . [PMC7251209]

These publications reflect Dr. Madden’s commitment to advancing knowledge in infectious diseases and his impact on clinical practice.